Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;6(2):131-138.
doi: 10.1517/17530059.2012.661711.

Multianalyte assay systems in the differential diagnosis of ovarian cancer

Brian M Nolen  1 , Anna E Lokshin
Affiliations

Multianalyte assay systems in the differential diagnosis of ovarian cancer

Brian M Nolen et al. Expert Opin Med Diagn. 2012 Mar.

Abstract

Introduction: The efficient triage of women diagnosed with a pelvic mass presents a current area of unmet need. Unnecessary surgical intervention performed on patients at a decreased risk of malignancy represents a significant source of preventable morbidity, anxiety and cost. Likewise, delayed or overlooked referral of patients harboring malignant tumors is strongly associated with diminished outcomes. Current tools including imaging modalities and the CA 125 blood test are of insufficient accuracy to overcome these challenges. The use of multianalyte assays systems which include additional biomarkers capable of complementing the performance of CA 125 may offer the best hope of improvement.

Areas covered: Recent findings regarding the use of multianalyte biomarker panels for the differential diagnosis of a pelvic mass are reviewed and discussed. Particular attention is paid to to the FDA approved ROMA and OVA1 tests. The development, validation, recent evaluation and comparative performances of these two tests are reviewed in detail.

Expert opinion: The performances achieved by the ROMA and OVA1 diagnostic tests represent significant milestones in the application of multianalyte assay systems into standard clinical practice. The overall impact and cost-effectiveness of widespread clinical use of these tools remains to be evaluated.

Keywords: OVA1; ROMA; biomarker; multianalyte; ovarian cancer; pelvic mass.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ries LAGMD, Krapcho M, Stinchcomg DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute; Bethesda, MD: 2008.
    1. Disaia PJ, Creasman WT. Clinical Gynecological Oncology. fifth edition Mosby-Year Book; St. Louis: 1997. The adnexal mass and early ovarian cancer; pp. 253–81.
    1. Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician. 1998;57:2471–6. 9–80. - PubMed
    1. Droegenmueller W. Benign gynecological lesions. In: Mishell DR Jr., editor. Comprehensive Gynecology. 4th edition Mosby; St. Louis (MO): 2001. pp. 479–525.
    1. Stany MP, Hamilton CA. Benign disorders of the ovary. Obstet Gynecol Clin North Am. 2008;35:271–84. ix. - PubMed